Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. During the same period last year, the business earned $0.14 EPS.

In terms of how AMNEAL PHARMACEUTICALS INC fares relative to all US stocks, note that its average analyst price target is greater than 128.23% of that group. In terms of how AMNEAL PHARMACEUTICALS INC ...

Known for his roles in Kuch Reet Jagat Ki Aisi Hai and Dahej Daasi, he anticipates a fresh approach to this strong negative role. Saurabh's acting journey started with inspiration from his father ...

Amneal Pharmaceuticals (AMRX) “announced that the FDA has accepted for review its Biologics Licensing Application for two proposed denosumab biosimilars referencing Prolia and XGEVA. mAbxience ...

Prajakta Koli and her longtime beau Vrishank Khanal tied the knot on February 25. Over the last few days, many photos and videos from the dreamy wedding have made their way to social media. Prajakta ...

In this article, we are going to take a look at where Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) stands against other best weight loss drug stocks to buy according to analysts. Most people have ...

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q4 2024 Earnings Call Transcript February 28, 2025 Amneal Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.10031 EPS ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

Revenue: US$2.79b (up 17% from FY 2023). Net loss: US$116.9m (loss widened by 39% from FY 2023). US$0.38 loss per share. Revenue was in line with analyst estimates. Earnings per share (EPS) missed ...

On raw material sourcing, he said the proposed factory at Jhagadia in Gujarat is in close proximity to the copper-producing facilities in Gujarat. Group entity Hindalco Industries also operates a ...

Good morning and welcome to the Amneal Pharmaceuticals Fourth Quarter 2024 Earnings Call. I'd now turn the call over to Amneal's Head of Investor Relations, Tony DiMeo. Please go ahead.

Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.15 per share. This compares to earnings of $0.14 per share a year ago.